Personalizovaná farmakoterapie digoxinem
[Personalized pharmacotherapy of digoxin]
Language Czech Country Czech Republic Media print
Document type Journal Article
PubMed
26075848
PII: 52310
- MeSH
- Bayes Theorem MeSH
- Digoxin pharmacokinetics MeSH
- Cardiotonic Agents pharmacokinetics MeSH
- Humans MeSH
- Drug Monitoring methods MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Heart Failure blood drug therapy MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Aged, 80 and over MeSH
- Aged MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Names of Substances
- Digoxin MeSH
- Cardiotonic Agents MeSH
INTRODUCTION: Therapeutic and toxic effects of digoxin are related to its serum concentrations, recent evidence suggests that a lower therapeutic range 0.5-0.9 ng/ml is associated with reduced mortality. AIM: To show the advantages of therapeutic drug monitoring for dosing of digoxin. METHOD: Trough serum levels of digoxin were estimated by immunoassay MEIA (AxSym Abbott). The long term serum concentration - time profile of digoxin has been predicted by the Bayesian analysis computer program MW-Pharm 3.30 MediWare. RESULTS: Sex case reports of the patients between 71 to 92 years are presented to show the different doses to receive digoxin levels in the therapeutic range. The doses varies between 0.03-0.25 mg per day. CONCLUSION: Therapeutic drug monitoring is very usefull for prediction of serum level of digoxin. There is no need to wait for a steady-state condition before performing therapeutic drug monitoring.
Cystatin C may be better than creatinine for digoxin dosing in older adults with atrial fibrillation